DarioHealth (DRIO) vs. Its Peers Critical Analysis

DarioHealth (NASDAQ:DRIO) is one of 93 public companies in the “Healthcare Technology” industry, but how does it contrast to its rivals? We will compare DarioHealth to related companies based on the strength of its profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Profitability

This table compares DarioHealth and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DarioHealth	-169.87%	-54.81%	-33.36%
DarioHealth Competitors	-754.24%	-30.01%	-15.66%

Earnings & Valuation

This table compares DarioHealth and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
DarioHealth	$22.36 million	-$41.71 million	-0.42
DarioHealth Competitors	$342.33 million	-$24.15 million	12.92

DarioHealth’s rivals have higher revenue and earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

33.4% of DarioHealth shares are held by institutional investors. Comparatively, 42.4% of shares of all “Healthcare Technology” companies are held by institutional investors. 3.5% of DarioHealth shares are held by insiders. Comparatively, 16.2% of shares of all “Healthcare Technology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility and Risk

DarioHealth has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, DarioHealth’s rivals have a beta of 1.11, indicating that their average share price is 11% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for DarioHealth and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	1	1	3	0	2.40
DarioHealth Competitors	454	1535	2744	89	2.51

DarioHealth currently has a consensus price target of $9.00, suggesting a potential upside of 245.49%. As a group, “Healthcare Technology” companies have a potential upside of 40.81%. Given DarioHealth’s higher possible upside, equities analysts clearly believe DarioHealth is more favorable than its rivals.

Summary

DarioHealth rivals beat DarioHealth on 9 of the 13 factors compared.

DarioHealth Company Profile

DarioHealth Corp. is a digital health company that develops technology-enabled solutions for managing chronic conditions. Its platform combines connected medical devices, mobile applications, data analytics and personalized coaching to help individuals monitor and improve their health. The company’s offerings have focused on conditions including diabetes, hypertension, musculoskeletal disorders and behavioral health. Products and services may include connected blood glucose and blood pressure monitoring, digital programs for pain and mobility management, health coaching, educational content and tools that support healthier daily habits.